Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom
Drug developers should attempt to limit the dosing of these medications to once-daily regimens, avoid surface roughness, and develop formulations that can be taken without regard to the timing of meals to the greatest extent possible.
Authors
- Sally-Anne Dews (ORCID: https://orcid.org/0000-0003-0941-5379)
- Brett Hauber (ORCID: https://orcid.org/0000-0003-3129-7268)
- Joshua Coulter (ORCID: https://orcid.org/0000-0002-1795-8536)
- Debra Montague
- C. Doody
- Amy S. Antipas
- Michaela Ogden-Barker
- Angela Terry
- Louis Edward Baig (ORCID: https://orcid.org/0009-0002-6112-0703)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Croydon College (GB)
- CRUK Lung Cancer Centre of Excellence (GB)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1007/s41030-024-00279-7
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Roy Castle Lung Cancer Foundation
- Pfizer UK